Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom

@inproceedings{Bewley2018CosteffectivenessOA,
  title={Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom},
  author={A. Bewley and Jonathan Barker and Farhan Mughal and H{\'e}l{\`e}ne Cawston and Vidya Damera and James R.G. Morris and Tom Tencer},
  year={2018}
}
AbstractPurpose: Apremilast, an oral phosphodiesterase-4 inhibitor, is effective and well tolerated in the treatment of moderate-to-severe psoriasis. The cost-effectiveness of introducing apremilas... 

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

  • Health technology assessment
  • 2006
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

The cost of biologics for psoriasis is increasing

  • Drugs in context
  • 2014
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.

  • The British journal of dermatology
  • 2012
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2011
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL